Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Mar;5(2):85-98.
doi: 10.1177/2040622313518227.

Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases

Khuder Alagha  1 , Alain Palot  1 , Tunde Sofalvi  1 , Laurie Pahus  1 , Marion Gouitaa  1 , Celine Tummino  1 , Stephanie Martinez  1 , Denis Charpin  1 , Arnaud Bourdin  2 , Pascal Chanez  1
Affiliations
Review

Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases

Khuder Alagha et al. Ther Adv Chronic Dis. 2014 Mar.

Abstract

Acetylcholine (neuronal and non-neuronal origin) regulates bronchoconstriction, and mucus secretion. It has an inflammatory effect by inducing attraction, survival and cytokine release from inflammatory cells. Muscarinic receptors throughout the bronchial tree are mainly restricted to muscarinic M1, M2 and M3 receptors. Three long-acting muscarinic receptor antagonists (LAMAs) were approved for the treatment of chronic obstructive pulmonary disease (COPD) in Europe: once-daily tiotropium bromide; once-daily glycopyrronium bromide; and twice-daily aclidinium bromide. All have higher selectivity for M3 receptors than for M2 receptors, and dissociate more slowly from the M3 receptors than they do from the M2 receptors. Some LAMAs showed anti-inflammatory effects [inhibition of neutrophil chemotactic activity and migration of alveolar neutrophils, decrease of several cytokines in the bronchoalveolar lavage (BAL) including interleukin (IL)-6, tumor necrosis factor (TNF)-α and leukotriene (LT)B4] and antiremodeling effects (inhibition of mucus gland hypertrophy and decrease in MUC5AC-positive goblet cell number, decrease in MUC5AC overexpression). In the clinic, LAMAs showed a significant improvement of forced expiratory volume in 1 second (FEV1), quality of life, dyspnea and reduced the number of exacerbations in COPD and more recently in asthma. This review will focus on the three LAMAs approved in Europe in the treatment of chronic airway diseases.

Keywords: aclidinium bromide; asthma; chronic obstructive pulmonary disease; glycopyrronium bromide; long-acting muscarinic receptor antagonists; tiotropium bromide.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The author declares that there is no conflict of interest.

Figures

Figure 1.
Figure 1.
Muscarinic receptors.
See this image and copyright information in PMC

References

    1. An S., Bai T., Bates J., Black J., Brown R., Brusasco V., et al. (2007) Airway smooth muscle dynamics: a common pathway of airway obstruction in asthma. Eur Respir J 29: 834–860 - PMC - PubMed
    1. Arai N., Kondo M., Izumo T., Tamaoki J., Nagai A. (2010) Inhibition of neutrophil elastase-induced goblet cell metaplasia by tiotropium in mice. Eur Respir J 35: 1164–1171 - PubMed
    1. Asano K., Shikama Y., Shibuya Y., Nakajima H., Kanai K., Yamada N., et al. (2008) Suppressive activity of tiotropium bromide on matrix metalloproteinase production from lung fibroblasts in vitro. Int J Chron Obstruct Pulmon Dis 3: 781–789 - PMC - PubMed
    1. Asano K., Shikama Y., Shoji N., Hirano K., Suzaki H., Nakajima H. (2010) Tiotropium bromide inhibits TGF-beta-induced MMP production from lung fibroblasts by interfering with Smad and MAPK pathways in vitro. Int J Chron Obstruct Pulmon Dis 5: 277–286 - PMC - PubMed
    1. Bateman E., Kornmann O., Schmidt P., Pivovarova A., Engel M., Fabbri L. (2011) Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol 128: 315–322 - PubMed

LinkOut - more resources